Mecox Pharma-B Starts Patient Enrollment in Phase Ib/II Trial of MT1002 for Acute Ischemic Stroke
2026-07-05 05:24:53
Mecox Pharma-B (02335.HK) said its Phase Ib/II clinical trial of MT1002, an in-house acute ischemic stroke candidate, has enrolled its first patient, according to 36Kr. The company described MT1002 as a dual-target antagonist of coagulation factor II and GPIIb/IIIa, with both anticoagulant and antiplatelet effects. The multicenter Phase Ib/II study is designed in two parts: the first evaluates safety and pharmacokinetics, while the second will further assess the therapy in a larger patient population through randomization and comparison against standard treatment. Mecox Pharma-B listed on the Hong Kong Stock Exchange on June 24, 2026.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
麦科医药-B：MT1002试验完成首例入组Next article：
地缘政治 | 印度车主抗议莫迪生物燃料计划
